Top

Published in:

01-09-2024 | Juvenile Dermatomyositis | Review

Treatment of calcinosis cutis associated with autoimmune connective tissue diseases

Authors: Charles B. Lau, Gideon P. Smith

Published in: Archives of Dermatological Research | Issue 7/2024

Abstract

Calcinosis cutis is a condition that is commonly associated with autoimmune connective tissue diseases. It is characterized by the deposition of insoluble calcium salts in the skin and subcutaneous tissue, which can cause pain, impair function, and have significant impacts on quality of life. Calcinosis cutis is difficult to manage because there is no generally accepted treatment: evidence supporting treatments is mostly comprised of case reports and case series, sometimes yielding mixed findings. Both pharmacologic and procedural interventions have been proposed to improve calcinosis cutis, and each may be suited to different clinical scenarios. This review summarizes current treatment options for calcinosis cutis, with discussion of recommendations based on patient-specific factors and disease severity.

Dima A, Balanescu P, Baicus C (2014) Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med 52(2):55–67PubMed

Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E (2011) Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol 65(1):1–12 quiz 13–14. https://doi.org/10.1016/j.jaad.2010.08.038CrossRefPubMed

Jiménez-Gallo D, Ossorio-García L, Linares-Barrios M (2015) Calcinosis Cutis and Calciphylaxis. Actas Dermo-Sifiliográficas (English Edition) 106(10):785–794. https://doi.org/10.1016/j.adengl.2015.10.018CrossRef

Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in Rheumatic diseases. Semin Arthritis Rheum 34(6):805–812. https://doi.org/10.1016/j.semarthrit.2005.01.016CrossRefPubMed

Goel SK, Bellovich K, McCullough PA (2011) Treatment of severe metastatic calcification and Calciphylaxis in Dialysis patients. Int J Nephrol 2011:701603. https://doi.org/10.4061/2011/701603CrossRefPubMedPubMedCentral

Edsall LC, English JC III, Patterson JW (2004) Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 31(3):247–253. https://doi.org/10.1111/j.0303-6987.2004.00169.xCrossRefPubMed

Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47(4):505–511. https://doi.org/10.1067/mjd.2002.122196CrossRefPubMed

Valenzuela A, Chung L (2022) Subcutaneous calcinosis: is it different between systemic sclerosis and dermatomyositis? J Scleroderma Relat Disord 7(1):7–23. https://doi.org/10.1177/23971983211053245CrossRefPubMed

Balin SJ, Wetter DA, Andersen LK, Davis MDP (2012) Calcinosis Cutis Occurring in Association with Autoimmune connective tissue disease: the Mayo Clinic Experience with 78 patients, 1996–2009. Arch Dermatol 148(4):455–462. https://doi.org/10.1001/archdermatol.2011.2052CrossRefPubMed

10.

Valenzuela A, Baron M, Rodriguez-Reyna TS et al (2020) Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Semin Arthritis Rheum 50(5):891–896. https://doi.org/10.1016/j.semarthrit.2020.06.007CrossRefPubMedPubMedCentral

11.

Morardet L, Avouac J, Sammour M et al (2016) Late Nailfold Videocapillaroscopy Pattern Associated with Hand Calcinosis and Acro-Osteolysis in systemic sclerosis. Arthritis Care Res 68(3):366–373. https://doi.org/10.1002/acr.22672CrossRef

12.

Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993–2000. https://doi.org/10.1056/NEJM199312303292704CrossRefPubMed

13.

Ballow M (1991) Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 68(6 Suppl):1430–1436. https://doi.org/10.1002/1097-0142(19910915)68:6+<1430::aid-cncr2820681405>3.0.co;2-4CrossRefPubMed

14.

Yang MC, Lee JH, Yang YH, Chiang BL (2008) Improvement of juvenile dermatomyositis with calcinosis universalis after treatment with intravenous immunoglobulin. Int J Rheum Dis 11(1):77–80. https://doi.org/10.1111/j.1756-185X.2008.00336.xCrossRef

15.

Schanz S, Ulmer A, Fierlbeck G (2008) Response of Dystrophic calcification to Intravenous Immunoglobulin. Arch Dermatol 144(5):585–587. https://doi.org/10.1001/archderm.144.5.585CrossRefPubMed

16.

Peñate Y, Guillermo N, Melwani P, Martel R, Hernández-Machín B, Borrego L (2009) Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 60(6):1076–1077. https://doi.org/10.1016/j.jaad.2008.09.051CrossRefPubMed

17.

Galimberti F, Li Y, Fernandez AP (2015) Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. J Am Acad Dermatol 73(1):174–176. https://doi.org/10.1016/j.jaad.2015.03.047CrossRefPubMed

18.

Shahani L (2012) Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. Case Rep 2012:bcr2012006629. https://doi.org/10.1136/bcr-2012-006629CrossRef

19.

Kalajian AH, Perryman JH, Callen JP (2009) Intravenous immunoglobulin therapy for Dystrophic Calcinosis Cutis: unreliable in our hands. Arch Dermatol 145(3):334. https://doi.org/10.1001/archdermatol.2008.620CrossRefPubMed

20.

de Paula DR, Klem FB, Lorencetti PG, Muller C, Azevedo VF (2013) Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 32(2):281–283. https://doi.org/10.1007/s10067-012-2124-zCrossRefPubMed

21.

Daoussis D, Antonopoulos I, Liossis SNC, Yiannopoulos G, Andonopoulos AP (2012) Treatment of systemic sclerosis-Associated calcinosis: a Case Report of Rituximab-Induced regression of CREST-Related calcinosis and review of the literature. Semin Arthritis Rheum 41(6):822–829. https://doi.org/10.1016/j.semarthrit.2011.11.007CrossRefPubMed

22.

Narváez J, Pirola JP, LLuch J, Juarez P, Nolla JM, Valenzuela A (2019) Effectiveness and safety of Rituximab for the treatment of refractory systemic sclerosis associated calcinosis: a case series and systematic review of the literature. Autoimmun rev 18(3):262–269. https://doi.org/10.1016/j.autrev.2018.10.006CrossRefPubMed

23.

Bader-Meunier B, Decaluwe H, Barnerias C et al (2011) Safety and Efficacy of Rituximab in severe Juvenile Dermatomyositis: results from 9 patients from the French autoimmunity and Rituximab Registry. J Rhuematol 38(7):1436–1440. https://doi.org/10.3899/jrheum.101321CrossRef

24.

Dubos M, Ly K, Martel C, Fauchais AL (2016) Is rituximab an effective treatment of refractory calcinosis? Case Rep 2016:bcr2015213179. https://doi.org/10.1136/bcr-2015-213179CrossRef

25.

Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS (2012) Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care 16(4):231. https://doi.org/10.1186/cc11304CrossRefPubMedPubMedCentral

26.

Campanilho-Marques R, Deakin CT, Simou S et al (2020) Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Therapy 22(1):79. https://doi.org/10.1186/s13075-020-02164-5CrossRef

27.

Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG (2014) The Presentation, Assessment, Pathogenesis, and treatment of Calcinosis in Juvenile Dermatomyositis. Curr Rheumatol Rep 16(12):467. https://doi.org/10.1007/s11926-014-0467-yCrossRefPubMedPubMedCentral

28.

Pachman LM, Liotta-Davis MR, Hong DK et al (2000) TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43(10):2368–2377. https://doi.org/10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8CrossRefPubMed

29.

Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47(6):877–880. https://doi.org/10.1093/rheumatology/ken074CrossRefPubMed

30.

Tosounidou S, MacDonald H, Situnayake D (2014) Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome. Rheumatology 53(5):960–961. https://doi.org/10.1093/rheumatology/ket365CrossRefPubMed

31.

Wendel S, Venhoff N, Frye BC et al (2019) Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib – A report of two cases. J Autoimmun 100:131–136. https://doi.org/10.1016/j.jaut.2019.03.003CrossRefPubMed

32.

Shneyderman M, Ahlawat S, Christopher-Stine L, Paik JJ (2021) Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology (Oxford) 60(11):e387–e388. https://doi.org/10.1093/rheumatology/keab421CrossRefPubMed

33.

Sözeri B, Demir F (2020) A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology 59(12):e140–e141. https://doi.org/10.1093/rheumatology/keaa360CrossRefPubMed

34.

Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and Sodium Thiosulfate for treatment of recalcitrant juvenile Dermatomyositis complicated by Ulceration and Calcinosis. J Pediatr 160(3):520–522. https://doi.org/10.1016/j.jpeds.2011.11.057CrossRefPubMedPubMedCentral

35.

Sukumaran S, Vijayan V (2020) Abatacept in the treatment of Juvenile Dermatomyositis-Associated calcifications in a 16-Year-old girl. Case Rep Rheumatol 2020:e4073879. https://doi.org/10.1155/2020/4073879CrossRef

36.

Gorrepati PL, Smith GP (2022) Treatments for calcinosis cutis in autoimmune connective tissue diseases. J Am Acad Dermatol 0(0). https://doi.org/10.1016/j.jaad.2022.03.029

37.

Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y (2001) An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 144(4):894–897. https://doi.org/10.1046/j.1365-2133.2001.04153.xCrossRefPubMed

38.

Jiang X, Yi Q, Liu D, Wang S, Li L (2011) A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem. Int J Dermatol 50(1):74–77. https://doi.org/10.1111/j.1365-4632.2009.04449.xCrossRefPubMed

39.

Vinen CS, Patel S, Bruckner FE (2000) Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology 39(3):333–334. https://doi.org/10.1093/rheumatology/39.3.333CrossRefPubMed

40.

Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M (2005) Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol 15(2):102–104PubMed

41.

Sharma NL, Mahajan VK, Ranjan N, Sharma VC, Gupta M (2010) Systemic sclerosis sine scleroderma and calcinosis cutis: report of a rare case. Clin Rheumatol 29(2):215–219. https://doi.org/10.1007/s10067-009-1303-zCrossRefPubMed

42.

Oliveri MB, Palermo R, Mautalen C, Hübscher O (1996) Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 23(12):2152–2155PubMed

43.

Singh J, Paliwal VK, Bhargava P, Mathur DK (2017) Idiopathic calcinosis Cutis Universalis treated successfully with oral Diltiazem—A Case Report. Pediatr Dermatol 34(5):e241–e244. https://doi.org/10.1111/pde.13217CrossRefPubMed

44.

Talreja O, Cassagnol M (2023) Diltiazem. In: StatPearls. StatPearls Publishing; Accessed October 26, 2023. http://www.ncbi.nlm.nih.gov/books/NBK532937/

45.

Tajalli M, Qureshi AA (2019) Successful treatment of calcinosis cutis of fingertip in the setting of CREST syndrome with topical 20% sodium thiosulfate. JAAD Case Rep 5(11):988–990. https://doi.org/10.1016/j.jdcr.2019.08.011CrossRefPubMedPubMedCentral

46.

Smith GP (2013) Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease. J Am Acad Dermatol 69(3):e146–147. https://doi.org/10.1016/j.jaad.2013.03.022CrossRefPubMed

47.

Goossens J, Courbebaisse M, Caudron E et al (2017) Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: two cases. Semin Arthritis Rheum 47(3):451–455. https://doi.org/10.1016/j.semarthrit.2017.05.013CrossRefPubMed

48.

Wolf EK, Smidt AC, Laumann AE (2008) Topical Sodium Thiosulfate Therapy for Leg Ulcers with Dystrophic Calcification. Arch Dermatol 144(12):1560–1562. https://doi.org/10.1001/archderm.144.12.1560CrossRefPubMed

49.

Ricardo JW, Sun HY, Gorji M, Sebaratnam DF (2021) Topical sodium thiosulfate as treatment of calcinosis cutis: Case series and systematic review. J Am Acad Dermatol 0(0). https://doi.org/10.1016/j.jaad.2021.09.013

50.

Gunasekera NS, Maniar LEG, Lezcano C, Laga AC, Merola JF (2017) Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the setting of Lupus Panniculitis. JAMA Dermatology 153(9):944–945. https://doi.org/10.1001/jamadermatol.2017.0966CrossRefPubMed

51.

del Barrio-Díaz P, Moll-Manzur C, Álvarez-Veliz S, Vera-Kellet C (2016) Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy. Br J Dermatol 175(3):608–611. https://doi.org/10.1111/bjd.14412CrossRefPubMed

52.

Song P, Fett Nm, Lin J, Merola Jf, Costner M, Vleugels R (2018) a. lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. Br J Dermatol 178(6):1412–1415. https://doi.org/10.1111/bjd.15783CrossRefPubMed

53.

Howard RM, Smith GP (2020) Treatment of calcinosis cutis with sodium thiosulfate therapy. J Am Acad Dermatol 83(5):1518–1520. https://doi.org/10.1016/j.jaad.2020.06.996CrossRefPubMed

54.

Ma JE, Ernste FC, Davis MDP, Wetter DA (2019) Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017. Clin Exp Dermatol 44(5):e189–e192. https://doi.org/10.1111/ced.13782CrossRefPubMed

55.

Winter AR, Klager S, Truong R, Foley A, Sami N, Weinstein D (2020) Efficacy of intralesional sodium thiosulfate for the treatment of dystrophic calcinosis cutis: a double-blind, placebo-controlled pilot study. JAAD Int 1(2):114–120. https://doi.org/10.1016/j.jdin.2020.07.002CrossRefPubMedPubMedCentral

56.

Taborn J, Bole GG, Thompson GR (1978) Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann Intern Med 89(5 Pt 1):648–649. https://doi.org/10.7326/0003-4819-89-5-648CrossRefPubMed

57.

Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M (1986) Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 5(4):527–530PubMed

58.

Vereecken P, Stallenberg B, Tas S, de Dobbeleer G, Heenen M (1998) Ulcerated dystrophic calcinosis cutis secondary to localised linear scleroderma. Int J Clin Pract 52(8):593–594CrossRefPubMed

59.

Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC (2020) Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 22(1):28. https://doi.org/10.1186/s13075-020-2120-7CrossRefPubMedPubMedCentral

60.

Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62(3):267–269. https://doi.org/10.1136/ard.62.3.267CrossRefPubMedPubMedCentral

61.

Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E (2011) Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 65(1):15–22 quiz 23–24. https://doi.org/10.1016/j.jaad.2010.08.039CrossRefPubMed

62.

Reiter N, El-Shabrawi L, Leinweber B, Aberer E (2010) Subcutaneous morphea with dystrophic calcification with response to ceftriaxone treatment. J Am Acad Dermatol 63(2):e53–e55. https://doi.org/10.1016/j.jaad.2009.11.016CrossRefPubMed

63.

Poterucha TJ, Goldhaber SZ (2016) Warfarin and vascular calcification. Am J Med 129(6):635. .e1-4CrossRef

64.

Cukierman T, Elinav E, Korem M, Chajek-Shaul T (2004) Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 63(10):1341–1343. https://doi.org/10.1136/ard.2003.014431CrossRefPubMedPubMedCentral

65.

Yoshida S, Torikai K (1993) The effects of warfarin on calcinosis in a patient with systemic sclerosis. J Rheumatol 20(7):1233–1235PubMed

66.

Lassoued K, Saiag P, Anglade MC, Roujeau JC, Touraine RL (1988) Failure of warfarin in treatment of calcinosis universalis. Am J Med 84(4):795–796. https://doi.org/10.1016/0002-9343(88)90128-3CrossRefPubMed

67.

Metzger AL, Singer FR, Bluestone R, Pearson CM (1974) Failure of Disodium Etidronate in Calcinosis due to Dermatomyositis and Scleroderma. N Engl J Med 291(24):1294–1296. https://doi.org/10.1056/NEJM197412122912408CrossRefPubMed

68.

Rabens SF, Bethune JE (1975) Disodium etidronate therapy for Dystrophic cutaneous calcification. Arch Dermatol 111(3):357–361. https://doi.org/10.1001/archderm.1975.01630150077009CrossRefPubMed

69.

Mori H, Okada Y, Yamaoka K, Saito K, Tanaka Y (2012) Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy. J Bone Min Metab 30(1):114–118. https://doi.org/10.1007/s00774-011-0289-1CrossRef

70.

Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138(5):763–766. https://doi.org/10.1067/mpd.2001.112473CrossRefPubMed

71.

Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rhuematol 32(9):1837–1839

72.

Platter M, Pugmire B, Patel R (2021) Resolution of calcinosis using bisphosphonates in overlap syndrome - a case report. BMC Rheumatol 5(1):6. https://doi.org/10.1186/s41927-021-00176-5CrossRefPubMedPubMedCentral

73.

Cañas CA, Bonilla-Abadía F, Mejía M, Tobón GJ (2015) Recovery of severe muscular and fascial calcinosis after treatment with bisphosphonates in a child with Juvenile Dermatomyositis. J Clin Rheumatol 21(5):267–269. https://doi.org/10.1097/RHU.0000000000000264CrossRefPubMed

74.

Marco Puche A, Calvo Penades I, Lopez Montesinos B (2010) Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28(1):135–140PubMed

75.

Palaniappan P, Lionel AP, Kumar S (2014) Successful treatment of Calcinosis Cutis in Juvenile Dermatomyositis with Pamidronate. JCR: J Clin Rheumatol 20(8):454–455. https://doi.org/10.1097/RHU.0000000000000199CrossRefPubMed

76.

Martillotti J, Moote D, Zemel L (2014) Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. Pediatr Radiol 44(1):115–118. https://doi.org/10.1007/s00247-013-2738-6CrossRefPubMed

77.

Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77(1):70–72. https://doi.org/10.1016/j.jbspin.2009.04.011CrossRefPubMed

78.

Rauch L, Hein R, Biedermann T, Eyerich K, Lauffer F (2021) Bisphosphonates for the treatment of Calcinosis Cutis—A retrospective single-center study. Biomedicines 9(11):1698. https://doi.org/10.3390/biomedicines9111698CrossRefPubMedPubMedCentral

79.

Wananukul S, Pongprasit P, Wattanakrai P (1997) Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol 38(4):202–205. https://doi.org/10.1111/j.1440-0960.1997.tb01698.xCrossRefPubMed

80.

Wang WJ, Lo WL, Wong CK (1988) Calcinosis Cutis in Juvenile Dermatomyositis: remarkable response to Aluminum Hydroxide Therapy. Arch Dermatol 124(11):1721–1722. https://doi.org/10.1001/archderm.1988.01670110077022CrossRefPubMed

81.

Aihara Y, Mori M, Ibe M et al (1994) [A case of juvenile dermatomyositis with calcinosis universalis–remarkable improvement with aluminum hydroxide therapy]. Ryumachi 34(5):879–884PubMed

82.

Nakagawa T, Takaiwa T (1993) Calcinosis Cutis in Juvenile Dermatomyositis Responsive to Aluminum Hydroxide Treatment. J Dermatol 20(9):558–560. https://doi.org/10.1111/j.1346-8138.1993.tb01338.xCrossRefPubMed

83.

Nassim JR, Connolly CK (1970) Treatment of calcinosis Universalis with Aluminium Hydroxide. Arch Dis Child 45(239):118–121CrossRefPubMedPubMedCentral

84.

Park YM, Lee SJ, Kang H, Cho SH (2009) Large subcutaneous calcification in systemic lupus erythematosus: treatment with oral aluminum hydroxide administration followed by surgical excision. J Korean Med Sci 14(5):589–592. https://doi.org/10.3346/jkms.1999.14.5.589CrossRef

85.

Hudson PM, Jones PE, Robinson TWE, Dent CE (1974) Extensive Calcinosis with Minimal Scleroderma: Treatment of Ectopic Calcification with Aluminum Hydroxide. Proceedings of the Royal Society of Medicine. ;67(11):1166–1168. https://doi.org/10.1177/003591577406701130

86.

Shon NN, Yarbrough T, Patel P (2023) Aluminum Hydroxide. In: StatPearls. StatPearls Publishing; Accessed October 26, 2023. http://www.ncbi.nlm.nih.gov/books/NBK546669/

87.

Kawahara M, Kato-Negishi M (2011) Link between aluminum and the pathogenesis of Alzheimer’s Disease: the integration of the aluminum and amyloid Cascade hypotheses. Int J Alzheimers Dis 2011:276393. https://doi.org/10.4061/2011/276393CrossRefPubMedPubMedCentral

88.

Eddy MC, Leelawattana R, McAlister WH, Whyte MP (1997) Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab 82(11):3536–3542. https://doi.org/10.1210/jcem.82.11.4343CrossRefPubMed

89.

Gutierrez A Jr, Wetter DA (2012) Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 25(2):195–206. https://doi.org/10.1111/j.1529-8019.2012.01492.xCrossRefPubMed

90.

Skuterud E, Sydnes OA, Haavik TK (1981) Calcinosis in Dermatomyositis Treated with Probenecid. Scand J Rheumatol 10(2):92–94. https://doi.org/10.3109/03009748109095279CrossRefPubMed

91.

Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K (2006) Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rhuematol 33(8):1691–1693

92.

Harel L, Harel G, Korenreich L, Straussberg R, Amir J (2001) Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rhuematol 28(5):1129–1132

93.

Lee SS, Felsenstein J, Tanzer FR (1978) Calcinosis Cutis Circumscripta: treatment with an Intralesional Corticosteroid. Arch Dermatol 114(7):1080–1081. https://doi.org/10.1001/archderm.1978.01640190064023CrossRefPubMed

94.

Hazen PG, Walker AE, Carney JF, Stewart JJ (1982) Cutaneous calcinosis of Scleroderma: successful treatment with Intralesional adrenal steroids. Arch Dermatol 118(5):366–367. https://doi.org/10.1001/archderm.1982.01650170080035CrossRefPubMed

95.

Zare P, Heller D (2023) Treprostinil. In: StatPearls. StatPearls Publishing; Accessed November 1, 2023. http://www.ncbi.nlm.nih.gov/books/NBK545152/

96.

Chung MP, Valenzuela A, Li S et al (2022) A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis. Rheumatology 61(6):2441–2449. https://doi.org/10.1093/rheumatology/keab810CrossRefPubMed

97.

Chan AY, Li E (2005) Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis—old method, new discovery. Clin Rheumatol 24(2):172–173. https://doi.org/10.1007/s10067-004-1023-3CrossRefPubMed

98.

Sparsa A, Lesaux N, Kessler E et al (2005) Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol 53(5):S263–S265. https://doi.org/10.1016/j.jaad.2005.04.010CrossRefPubMed

99.

Beatty P, Killion L, Power R, Roche M (2021) Dystrophic calcinosis cutis successfully treated with extracorporeal shockwave lithotripsy. Clin Exp Dermatol 46(8):1656–1658. https://doi.org/10.1111/ced.14857CrossRefPubMed

100.

Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguiaï Z (2012) Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol 66(3):424–429. https://doi.org/10.1016/j.jaad.2010.12.035CrossRefPubMed

101.

Blumhardt S, Frey DP, Toniolo M, Alkadhi H, Held U, Distler O (2016) Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis. Clin Exp Rheumatol 34(Suppl 100):177–180PubMed

102.

Bottomley Ww, Goodfield M (1996) j. d., Sheehan-Dare R a. Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. British Journal of Dermatology. ;135(2):302–304. https://doi.org/10.1111/j.1365-2133.1996.tb01166.x

103.

Chamberlain AJ, Walker NPJ (2003) Successful palliation and significant remission of cutaneous calcinosis in CREST Syndrome with Carbon Dioxide laser. Dermatol Surg 29(9):968–970. https://doi.org/10.1046/j.1524-4725.2003.29261.xCrossRefPubMed

104.

Abrouk M, Nousari Y, Waibel JS (2020) Novel treatment of calcifications from dermatomyositis with picosecond and carbon dioxide laser. JAAD Case Rep 6(9):852–853. https://doi.org/10.1016/j.jdcr.2020.06.022CrossRefPubMedPubMedCentral

105.

Meissner M, Ochsendorf F, Kaufmann R, Letter (2010) Therapy of Calcinosis Cutis using erbium-doped Yttrium Aluminum Garnet Laser Treatment. Dermatol Surg 36(5):727–728. https://doi.org/10.1111/j.1524-4725.2010.01539.xCrossRefPubMed

106.

Saddic N, Miller JJ, Miller OF III, Clarke JT (2009) Surgical debridement of painful fingertip calcinosis Cutis in CREST Syndrome. Arch Dermatol 145(2):212–213. https://doi.org/10.1001/archderm.145.2.212-bCrossRefPubMed

107.

Cousins MAM, Jones DB, Whyte MP, Monafo WW (1997) Surgical management of calcinosis cutis universalis in systemic lupus erythematosus. Arthr Rhuem 40(3):570–572. https://doi.org/10.1002/art.1780400325CrossRef

108.

Welborn MC, Gottschalk H, Bindra R, Juvenile Dermatomyositis (2015) A case of Calcinosis Cutis of the elbow and review of the literature. J Pediatr Orthop 35(5):e43–46. https://doi.org/10.1097/BPO.0000000000000358CrossRefPubMed

109.

Minami A, Suda K, Kaneda K, Kumakiri M (1994) Extensive subcutaneous calcification of the forearm in systemic lupus erythematosus. J Hand Surg Br 19(5):638–641. https://doi.org/10.1016/0266-7681(94)90134-1CrossRefPubMed

110.

Wu JJ, Metz BJ (2008) Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg 34(4):575–577. https://doi.org/10.1111/j.1524-4725.2007.34106.xCrossRefPubMed

Title: Treatment of calcinosis cutis associated with autoimmune connective tissue diseases
Authors: Charles B. Lau
Gideon P. Smith
Publication date: 01-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: Juvenile Dermatomyositis
Dermatomyositis
Systemic Sclerosis
Published in: Archives of Dermatological Research / Issue 7/2024
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-024-03148-0

EASD 2024

Springer Medicine

Treatment of calcinosis cutis associated with autoimmune connective tissue diseases

Abstract

EASD 2024

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2024

Targeting sebaceous slands: a review of selective photothermolysis for Acne Vulgaris treatment

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry

Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry

Enhanced bioenergetic cellular activity with metabolic switch to aerobic glycolysis in Keloid and Folliculitis Keloidalis Nuchae

Variation in clinical presentation of pediatric-onset and adult-onset atopic dermatitis: a retrospective, single-center, chart review of adults with atopic dermatitis from the United States

Possible therapeutic target MKK3 in blister formation in pemphigus